Results 31 to 40 of about 1,443,667 (357)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma

JAMA Network Open, 2022
This case series describes the kinetics of humoral deficiency in patients with relapsed refractory multiple myeloma treated with bispecific antibodies, the infectious complications, and response to COVID-19 immunization.
Lindsay Hammons, A. Szabo, A. Janardan, B. Dhakal, S. Chhabra, Anita D’Souza, Meera Mohan   +6 more
semanticscholar   +1 more source

A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity

Cancer Research, 2022
A conditionally active EGFR-CD3 T cell–engaging Probody therapeutic expands the safety window of bispecific antibodies while maintaining efficacy in preclinical solid tumor settings.
Leila M Boustany, S. L. LaPorte, Laurie Wong, Clayton White, Veena Vinod, Joel Shen, W. Yu, David Koditek, Michael B Winter, Stephen Moore, Li Mei, L. Diep, Yuanhui Huang, Souchun Liu, O. Vasiljeva, J. West, J. Richardson, B. Irving, M. Belvin, W. Kavanaugh   +19 more
semanticscholar   +1 more source

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

Cancers, 2021
Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables soldier cells of the immune system to recognize and kill tumor cells.
J. Middelburg, K. Kemper, P. Engelberts, A. Labrijn, J. Schuurman, T. van Hall   +5 more
semanticscholar   +1 more source

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade

Nature Communications, 2021
Immune checkpoint inhibitors demonstrate clinical activity in many tumor types, however, only a fraction of patients benefit. Combining CD137 agonists with these inhibitors increases anti-tumor activity preclinically, but attempts to translate these ...
C. Geuijen, P. Tacken, Liang-Chuan S. Wang, R. Klooster, Pieter Fokko van Loo, Jing Zhou, A. Mondal, Yao-bin Liu, Arjen Kramer, T. Condamine, A. Volgina, L. Hendriks, Hans van der Maaden, E. Rovers, S. Engels, F. Fransen, Renate den Blanken-Smit, Vanessa Zondag-van der Zande, Abdul Basmeleh, Willem Bartelink, Ashwin Kulkarni, W. Marissen, Cheng-Yen Huang, Leslie Hall, S. Harvey, Soyeon Kim, Miguel Ángel Martínez, S. O’Brien, E. Moon, S. Albelda, C. Kanellopoulou, Shaun Stewart, H. Nastri, Alexander B. H. Bakker, P. Scherle, T. Logtenberg, G. Hollis, J. de Kruif, R. Huber, P. Mayes, M. Throsby   +40 more
semanticscholar   +1 more source

PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects

BioFactors, Volume 48, Issue 6, Page 1226-1249, November/December 2022., 2022
Abstract Ocular allergies are becoming more prevalent as more airborne pollutants, irritants and microbes pervade our environment. Inflammatory and allergic mediators released by dendritic and mast cells within the conjunctiva cause allergic conjunctivitis (AC), a prevalent ocular surface disorder that affects >40% of the world's human population on a ...
Najam A. Sharif
wiley   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

Oncoimmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, H. Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
semanticscholar   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Therapeutic Advances in Vaccines and Immunotherapy, 2018
Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety.
Eva Dahlén, Niina Veitonmäki, Per Norlén   +2 more
openaire   +3 more sources

Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20

Scientific Reports, 2023
Complement-dependent cytotoxicity (CDC), which eliminates aberrant target cells through the assembly and complex formation of serum complement molecules, is one of the major effector functions of anticancer therapeutic antibodies.
Sang Min Lee, Sung-Won Min, Hyeong Sun Kwon, Gong-Deuk Bae, Ji Hae Jung, Hye In Park, Seung Hyeon Lee, Chung Su Lim, Byoung Joon Ko, Ji Chul Lee, Sang Taek Jung   +10 more
doaj   +1 more source

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Clinical Cancer Research, 2021
Purpose: Investigate the safety and efficacy of LY3415244, a TIM-3/PD-L1 bispecific antibody that blocks TIM-3 and PD-L1 in patients with advanced solid tumors. Patients and Methods: A phase I, multicenter, open-label study was conducted in patients with
M. Hellmann, Nicoletta Bivi, B. Calderon, Toshio Shimizu, B. Delafontaine, Z. Liu, Anna M. Szpurka, Victoria Copeland, F. Hodi, S. Rottey, P. Aftimos, Y. Piao, L. Gandhi, V. R. Galvão, C. Leow, T. Doi   +15 more
semanticscholar   +1 more source